Member Info for bignose58

I wonder if the following extracted information will be of any use to our FDA approval effort ?

During 2018 the European Medicines Agency renewed the product’s marketing approval and waived the need for a 
post-authorization study (Drug Utilization Study) to evaluate the utilization of the drug in clinical practice through 
the monitoring of prescription databases. 

And no mention of continued launches.......Maybe they feel its just not worth it ???

One would think the numbers would be better for the 2nd half with rescripts...........but they have actually declined which would indicate less than a monthly shag.

And remember we only get 15% of that..........120k Euros, that's only enough to pay JG for one month and 3 days.

And They are trying to convince shareholders that the first year sales in China are expected to reach 9mill sufferers.....One cannot even prorate the European launch numbers to get to that figure..

Very true :-)

Whoops. That shd have been 2018. :-O

Based on the time line contained in the announcement of the 13th July 2017 and adjusted for the delay, the study shd complete by the end of this month or very early next month.

So it dropped just as quickly as it rose. The relentless selling of traders just wont allow any gains, although we are up a little from a few weeks ago. Then again, the recent jump in exchange rate erodes all of that.

SS22, I was expecting far better from you and your mates....Maybe next time ehh.....LOL

The.Italian,

Even if Bothwell is being a little tongue in cheek given the content of his posts regarding the recent articles, there could be some underlying significant interest forming from the fact that we are into the FDA process with the EU approval already under our belt. As I mentioned before, what can 100 ppl in a lab demonstrate that 50odd k have not already given the feedback has only been very positive ???

Could be exciting times this year. We just have to wait and see.....Probably drop like a bomb tomorrow.....LOL

Bothwell,

Lets hope so. Maybe there are some prudent investors who watch whats being currently FDA'd and then do some due diligence and then invest on the possible exponential opportunities. Since we are now listed as starting our FDA process, PLE/RPG/Forticin could now be under the watchful eye of said people. Once they also see we have a license agreement for the EU and now China, they undoubtedly will be interested. I am sure there are many that have no interest until an FDA process is officially started.

If this does take off from some now well deserved interest, it could be the catalyst for a decent rise to a more appropriate valuation. the HK investor community will not miss a chance to jump if there is more overseas interest.

Still many sellers out there. One would think given the upcoming prospects, they would hold onto what they have. I guess traders will be traders getting their 5%, which, if they manage a couple a month, provides a decent income,

Morning The.Italian,

Well it has been about 9 months since he was last on here predicting 1HK dollar and it went up to 0.46. (probably mentioned 1 HK dollar making sure only his mates sold out)

Could be a cyclical event and after 9 months a Pin' & a Din' all the other companies, it has returned back here ... ;-)

The beginings of another orchestrated pump n dump ?

Come on SS22, spill the beans. How much this time? ...... Lol

Bothwell

If you did say Bignose, I certainly didn't hear you........maybe cos I"m on the other side of the planet......LOL

But yes, some progress.....lets just hope it continues without any glitches. Maybe it will now its out of the hands of the RPG management.....LOL

huge "share volume" (not sure why that was removed - even if read backwards there is no subliminal message....LOL)

The second article is more interesting.

Why would someone on wall street write about a small company trading in HK ?

The two main insider investors are of course Big Jim and Jamie so why not write that ? But I am sure the article is quite true regarding international investors, although I would like to know where he/she gets their information from as to who else is or is not invested. No mention of the huge ************** following the UK launch, unless no one was taking positions as speculated by some here. Was it really just day traders.......about 1.5billion shares traded in a matter of days surely not (and remembering that only 60 to 70% of total shares were available as free float to trade). I don't suppose we will ever get to the bottom of this.

This seems just BS:
The general public, who are mostly retail investors, collectively hold 73% of Regent Pacific Group shares. This size of ownership gives retail investors collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

This is certainly true:
As far I can tell there isn’t analyst coverage of the company, so it is probably flying under the radar.

Pity he/she didn't list the major share holders (apart from Jim n Jamie) so we can contact them to try and oust the CEO or make a pay reduction.

No mention of the product, so what is the purpose of the article and as mentioned above why would someone on Wall Street want to write about the company ?

Morning all.

Holds investments in healthcare and life sciences companies in China, Hong Kong, the United Kingdom, North America, Latin America, the Asia Pacific, and internationally.

Well that's certainly not true and very very misleading. What investments other than PLE in the UK have they made in companies in any of these places ? They may have license agreements for Europe, Asia and China but that is not the same as investments is it. And why mention North and Latin America. RPG don't even have any license agreements with anyone in either of these regions ?

All my own opinion of course .... :-)

Bothwell,

At least the gov website was updated on the 11th Feb. Seems a couple more regions have now started recruiting, so at least some progress there......something positive. :-)

https://clinicaltrials.gov/ct2/show/NCT03578783

Matt

Not spoken to him for a while as not much to discuss. All he said last time was that it’ll now be driven by sales and with regard to the China license he was hopeful of a favourable outcome. But if that didn’t happen, 3 to 5 years is a joke. He has no faith in JG or the bod too which seems to be a general attitude given all the false hopes on time scales. It’s a case of wait and see now.

Matt

It’s pretty obvious it’s not going to be much. What did we estimate based on projections of the first 4months ? 150 to 200k and that’s being optimistic given no further launches for last year.

Interesting that they predict 9mill sales in the first year alone and that's after the known disappointing first year European sales.... :-)

That should have been 300K from Orient.... ;-)